Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$422M |
| 2 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$411M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$351M |
| 4 |
Pfizer
PFE
|
+$331M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$319M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.28B |
| 2 |
Meta Platforms (Facebook)
META
|
+$989M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$953M |
| 4 |
Amazon
AMZN
|
+$816M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$782M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 92.23% |
| 2 | Technology | 2.06% |
| 3 | Consumer Discretionary | 1.41% |
| 4 | Healthcare | 0.83% |
| 5 | Financials | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11676
PharmaCyte Biotech
PMCB
$5.8M
| $47.6K | ﹤0.01% |
+22,028
| New | +$47.7K |
|
|
EGIO
11677
DELISTED
Edgio, Inc. Common Stock
EGIO
| $47.5K | ﹤0.01% |
3,467
-14,864
| -81% | -$367K |
|
11678
Larimar Therapeutics
LRMR
$421M
| $47.2K | ﹤0.01% |
+10,375
| New | +$35K |
|
11679
PUT
NovaGold Resources
NG
$4B
| $47.1K | ﹤0.01% |
12,600
-2,000
| -14% | -$7.5K |
|
|
RGLS
11680
CALL
DELISTED
Regulus Therapeutics
RGLS
| $47K | ﹤0.01% |
36,700
+1,500
| +4% | +$2K |
|
|
NOTE
11681
DELISTED
FiscalNote
NOTE
| $46.9K | ﹤0.01% |
3,427
+1,794
| +110% | +$29.6K |
|
|
SELF
11682
CALL
Global Self Storage
SELF
$64M
| $46.8K | ﹤0.01% |
+10,100
| New | +$46.9K |
|
11683
CALL
Arcutis Biotherapeutics
ARQT
$3.13B
| $46.2K | ﹤0.01% |
+14,300
| New | +$38.9K |
|
11684
Nektar Therapeutics
NKTR
$2.55B
| $45.9K | ﹤0.01% |
5,414
-3,949
| -42% | -$29.9K |
|
|
HYZN
11685
CALL
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $45.8K | ﹤0.01% |
1,018
| – | – |
|
11686
CALL
Anixa Biosciences
ANIX
$122M
| $45.8K | ﹤0.01% |
11,800
-26,000
| -69% | -$87.7K |
|
11687
CALL
Barnes & Noble Education
BNED
$424M
| $45.7K | ﹤0.01% |
+307
| New | +$34.1K |
|
11688
Airgain
AIRG
$68.9M
| $45.7K | ﹤0.01% |
+12,825
| New | +$40.3K |
|
11689
Data I/O
DAIO
$31M
| $45.6K | ﹤0.01% |
15,503
-15,996
| -51% | -$51.5K |
|
11690
CALL
Oramed Pharmaceuticals
ORMP
$212M
| $45.5K | ﹤0.01% |
+19,700
| New | +$42.1K |
|
11691
Orion Energy Systems
OESX
$109M
| $45.3K | ﹤0.01% |
+5,232
| New | +$51.5K |
|
|
ADAP
11692
DELISTED
Adaptimmune Therapeutics
ADAP
| $45.1K | ﹤0.01% |
56,846
-110,042
| -66% | -$62K |
|
11693
PUT
Blend Labs
BLND
$364M
| $44.9K | ﹤0.01% |
17,600
-15,600
| -47% | -$23.5K |
|
11694
Atara Biotherapeutics
ATRA
$92.8M
| $44.8K | ﹤0.01% |
3,497
-5,057
| -59% | -$118K |
|
|
VXRT
11695
DELISTED
Vaxart
VXRT
| $44.8K | ﹤0.01% |
78,139
-30,761
| -28% | -$21.3K |
|
|
BNBX
11696
DELISTED
BNB PLUS CORP
BNBX
| $44.6K | ﹤0.01% |
5
-4
| -44% | -$51.8K |
|
11697
NextTrip
NTRP
$20.7M
| $44.5K | ﹤0.01% |
15,000
+3,054
| +26% | +$10.9K |
|
11698
Gaia
GAIA
$40.4M
| $44.5K | ﹤0.01% |
16,493
+3,188
| +24% | +$8.57K |
|
11699
CALL
Fusion Fuel Green
HTOO
$14.2M
| $44.5K | ﹤0.01% |
1,134
+374
| +49% | +$11.6K |
|
|
WBX
11700
PUT
Wallbox
WBX
$70.3M
| $44.5K | ﹤0.01% |
+1,270
| New | +$45.4K |
|
Similar funds
Jeff Yass's Q4 2023 Portfolio in Review
As of Q4 2023, Jeff Yass held 13,823 positions worth $525B, up 9.3% from $481B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jeff Yass's Q4 2023 filing shows 1,903 new, 5,066 increased, 5,122 reduced and 1,577 closed positions. Its largest new stake was Vanguard Emerging Markets Government Bond ETF: 471,007 shares worth $30M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.28B.
By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 91% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q4 2023 buy was Vanguard Emerging Markets Government Bond ETF: 471,007 shares worth $30M.
- Jeff Yass added most to Alibaba in Q4 2023, an estimated $422M increase.
- Jeff Yass's biggest Q4 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.28B.
- Jeff Yass fully exited VMware, Inc in Q4 2023, selling an estimated $313M.
- Jeff Yass's ten largest holdings make up 24% of its $525B portfolio in Q4 2023.
- Jeff Yass opened 1,903 new positions and closed 1,577 in Q4 2023.
- Jeff Yass's portfolio value rose 9.3% quarter-over-quarter to $525B.
Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.